Van Son Marieke J, Peters Max, Moerland Marinus A, Noteboom Juus L, Eppinga Wietse S, Davila Fajardo Raquel, Lagendijk Jan, Van der Voort van Zyp Jochem R
Department of Radiation Oncology, University Medical Center Utrecht.
Department of Radiotherapy, University Medical Center Utrecht.
Cureus. 2018 Apr 5;10(4):e2429. doi: 10.7759/cureus.2429.
Prostate cancer recurrences are common, even with twenty-first-century primary prostate cancer treatment modalities. The most common salvage treatment is (delayed) hormonal therapy, which is often associated with serious side-effects. Due to the risk of significant toxicity, whole-gland targeted salvage treatments remain unpopular. Consequently, developments in focal therapies have arisen. Magnetic resonance imaging (MRI)-guided focal salvage high-dose-rate brachytherapy (HDR-BT) is a novel treatment aiming for minimal toxicity in recurrent prostate cancer patients. Repeating focal treatment could, therefore, be possible in case of post-salvage recurrence. We report the case of a 77-year-old man who underwent repeat focal HDR-BT.
前列腺癌复发很常见，即使采用21世纪的原发性前列腺癌治疗方式也是如此。最常见的挽救性治疗是（延迟）激素治疗，这种治疗常常伴有严重的副作用。由于存在显著毒性风险，全腺体靶向挽救性治疗仍然不受欢迎。因此，聚焦治疗有了发展。磁共振成像（MRI）引导下的聚焦挽救性高剂量率近距离放射治疗（HDR-BT）是一种针对复发性前列腺癌患者力求毒性最小的新型治疗方法。因此，在挽救性治疗后复发的情况下，重复聚焦治疗是可行的。我们报告了一例接受重复聚焦HDR-BT治疗的77岁男性患者的病例。
